Pharmaxis to get milestone from Boehringer deal

18 May 2017

Australia’s Pharmaxis (ASX: PXS) saw its shares jump 11.5% to A$0.29 after it announced that it now expects to receive milestones from its collaboration with German family owned pharma major Boehringer Ingelheim on PXS-4728A, a potential treatment for non-alcoholic steatohepatitis (NASH).

In addition to a Phase II trial in NASH that is scheduled to start mid-year, Boehringer has confirmed that a Phase II study for a second disease indication will commence this year. Pharmaxis is due to receive milestone payments of 18 million euros ($20 million) for the start of a Phase II trial in NASH and 10 million euros for the second indication.

Boehringer acquired PXS‐4728A from Pharmaxis in May 2015 with initial clinical development focused on finding a treatment for the liver disease known as NASH. This involved an upfront payment of 27.5 million euros and a total potential deal value of over A$750 million ($555 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK